Ingevity Stock Forecast, Price & News

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ingevity in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Ingevity stock.
View analyst ratings for Ingevity or view top-rated stocks.

Wall Street analysts have given Ingevity a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Ingevity wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Ingevity saw a decrease in short interest in the month of August. As of August 13th, there was short interest totaling 839,600 shares, a decrease of 17.7% from the July 29th total of 1,020,000 shares. Based on an average daily volume of 206,700 shares, the days-to-cover ratio is currently 4.1 days. Currently, 2.2% of the company's shares are short sold.
View Ingevity's Short Interest.

Ingevity is scheduled to release its next quarterly earnings announcement on Tuesday, October 19th 2021.
View our earnings forecast for Ingevity.

Ingevity Co. (NYSE:NGVT) announced its earnings results on Wednesday, July, 28th. The company reported $1.55 earnings per share for the quarter, beating the consensus estimate of $1.21 by $0.34. The firm had revenue of $358.40 million for the quarter, compared to the consensus estimate of $331.55 million. Ingevity had a net margin of 16.00% and a trailing twelve-month return on equity of 37.34%.
View Ingevity's earnings history.

Ingevity's stock was trading at $38.80 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, NGVT shares have increased by 81.5% and is now trading at $70.41.
View which stocks have been most impacted by COVID-19.

Ingevity updated its FY 2021 earnings guidance on Wednesday, August, 4th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $1.32 billion-$1.36 billion, compared to the consensus revenue estimate of $1.33 billion.

3 brokerages have issued 12 month price targets for Ingevity's stock. Their forecasts range from $85.00 to $112.00. On average, they anticipate Ingevity's share price to reach $97.33 in the next year. This suggests a possible upside of 38.2% from the stock's current price.
View analysts' price targets for Ingevity or view top-rated stocks among Wall Street analysts.

2 employees have rated Ingevity CEO John Fortson on Glassdoor.com. John Fortson has an approval rating of 100% among Ingevity's employees. This puts John Fortson in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Ingevity include Olin (OLN), Johnson Matthey (JMPLY), Huntsman (HUN), Ashland Global (ASH), W. R. Grace & Co. (GRA), Balchem (BCPC), The Chemours (CC), Univar Solutions (UNVR), Livent (LTHM), Showa Denko K.K. (SHWDY), Kuraray (KURRY), Innospec (IOSP), GCP Applied Technologies (GCP), Ecovyst (ECVT) and Hawkins (HWKN).
View all of NGVT's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Ingevity investors own include Pfizer (PFE), AbbVie (ABBV), General Electric (GE), Verizon Communications (VZ), WestRock (WRK), Abbott Laboratories (ABT), The Boeing (BA), Costco Wholesale (COST), Dominion Energy (D) and Johnson & Johnson (JNJ).

Ingevity trades on the New York Stock Exchange (NYSE) under the ticker symbol "NGVT."

Ingevity's stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (11.15%), Vanguard Group Inc. (10.02%), Boston Partners (5.89%), State Street Corp (3.08%), LSV Asset Management (2.81%) and Broad Bay Capital Management LP (2.51%). Company insiders that own Ingevity stock include D Michael Wilson, Diane H Gulyas, Frederick J Lynch, John C Fortson, Michael P Smith, Richard B Kelson and Stuart Edward Jr Woodcock.
View institutional ownership trends for Ingevity.

NGVT stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Goldman Sachs Group Inc., Franklin Resources Inc., Broad Bay Capital Management LP, State Street Corp, Rice Hall James & Associates LLC, Southernsun Asset Management LLC, and Price T Rowe Associates Inc. MD.
View insider buying and selling activity for Ingevity or view top insider-selling stocks.

NGVT stock was acquired by a variety of institutional investors in the last quarter, including Teacher Retirement System of Texas, Maple Rock Capital Partners Inc., Millennium Management LLC, BNP PARIBAS ASSET MANAGEMENT Holding S.A., Castleark Management LLC, Calamos Advisors LLC, Primecap Management Co. CA, and Invesco Ltd.. Company insiders that have bought Ingevity stock in the last two years include D Michael Wilson, Diane H Gulyas, Frederick J Lynch, John C Fortson, Michael P Smith, and Richard B Kelson.
View insider buying and selling activity for Ingevity or or view top insider-buying stocks.

Shares of NGVT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of NGVT stock can currently be purchased for approximately $70.41.

Ingevity has a market capitalization of $2.78 billion and generates $1.22 billion in revenue each year. The company earns $181.40 million in net income (profit) each year or $4.88 on an earnings per share basis.

Ingevity employs 1,750 workers across the globe.

The official website for Ingevity is www.ingevity.com.

Ingevity is headquartered at 4920 O`Hear Avenue Suite 400, North Charleston SC, 29406.

Ingevity's mailing address is 4920 O`Hear Avenue Suite 400, North Charleston SC, 29406. The company can be reached via phone at (844) 643-8489 or via email at [email protected].